Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | PYGL | P06737 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | PYGM | P11217 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123098 | 0.88 | PYGL (0.83) | L3MBTL1TDP1KMT2ARAB9APYGL | |
| SCHEMBL12189439 | 0.85 | PYGM (0.66) | L3MBTL1TDP1KMT2ARAB9APYGL | |
| SCHEMBL12368199 | 0.85 | RAB9A (0.89) | L3MBTL1TDP1KMT2ARAB9AATM | |
| SCHEMBL12189446 | 0.84 | TDP1 (0.62) | L3MBTL1TDP1KMT2ARAB9APYGL | |
| SCHEMBL7118256 | 0.83 | PYGL (0.74) | L3MBTL1TDP1KMT2ARAB9APYGL | |
| SCHEMBL6802094 | 0.83 | KMT2A (1.00) | KMT2ARAB9ATSHRMAPK1MEN1 | |
| SCHEMBL11016717 | 0.82 | TSHR (0.68) | L3MBTL1TDP1KMT2ARAB9APYGL | |
| SCHEMBL27943418 | 0.82 | MAPT (0.67) | L3MBTL1TDP1KMT2ARAB9AATM | |
| SCHEMBL7123047 | 0.81 | PYGL (0.76) | L3MBTL1TDP1KMT2ARAB9APYGL | |
| SCHEMBL30462469 | 0.81 | FABP4 (0.57) | L3MBTL1TDP1KMT2ARAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8859620-B2 | Phthalanilate compounds and methods of use | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
| US-7041690-B2 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | L3MBTL1 3370/4885TDP1 2961/4885KMT2A 1142/4885 |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, EIF5B, POLI | L3MBTL1 4022/4885TDP1 2026/4885KMT2A 2664/4885 |
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | L3MBTL1 3370/4885TDP1 2961/4885KMT2A 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.